Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 28, 2007. The report addresses compliance with Section 306(a) of the Sarbanes-Oxley Act of 2002 regarding insider trading prohibitions during pension fund blackout periods.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice concerning employee benefit plan administration and does not contain financial performance data.
Material Changes
The filing details a transition in the administration of the US Retirement Savings Plan (401k), moving recordkeepers from Hewitt Associates to ACS effective July 1, 2007. This operational change necessitates a temporary restriction on employee access to plan accounts.
Guidance, Outlook, and Risks
- Blackout Period: Scheduled from 4:00 PM EST on June 28, 2007, to 8:00 AM EST on July 5, 2007. During this time, employees cannot access or trade in their 401k accounts.
- Trading Restrictions: Executive directors and principal officers are prohibited from trading GSK shares during the blackout period (June 28 at 4:00 PM EST through June 29).
- Company Close Period: A separate close period for designated employees runs from the close of business on June 29, 2007, until July 25, 2007.
Investor Verification Checklist
- Confirm the specific dates of the 401k blackout period (June 28–July 5, 2007) and the executive trading restriction window.
- Verify the transition of the US Benefit program recordkeeper from Hewitt Associates to ACS.
- Note that this filing contains no financial results; refer to Form 20-F or quarterly reports for financial metrics.